These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 21653603

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS, Frei CR.
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS, Hall RG.
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [Abstract] [Full Text] [Related]

  • 7. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR.
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
    Zelenitsky SA, Ariano RE.
    J Antimicrob Chemother; 2010 Aug; 65(8):1725-32. PubMed ID: 20558470
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR, Burgess DS.
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
    Kiffer CR, Mendes C, Kuti JL, Nicolau DP.
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
    Nomura K, Morikawa N, Ikawa K, Ikeda K, Fujimoto Y, Shimizu D, Taniguchi K, Shimura K, Kanbayashi Y, Komori T, Matsumoto Y, Fujita N, Shimazaki C, Taniwaki M.
    J Antimicrob Chemother; 2008 Apr; 61(4):892-900. PubMed ID: 18276604
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.
    Zelenitsky SA, Ariano RE, Zhanel GG.
    J Antimicrob Chemother; 2011 Feb; 66(2):343-9. PubMed ID: 20926397
    [Abstract] [Full Text] [Related]

  • 19. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA, Kuti JL, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.